|
4 Companies |
|
8 Products |
|
8 Products |
|
12 Mechanisms of Action |
|
0 Trials |
|
14 News |
|
- | Trial completion: Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 (clinicaltrials.gov) - Jul 5, 2018
P3, N=368, Completed, Sponsor: Karolinska University Hospital
Active, not recruiting --> Completed
- | Trial termination: T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders (clinicaltrials.gov) - Jan 24, 2018
P2/3, N=22, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Replaced by another protocol
- | etoposide IV / Generic mfg.
Trial primary completion date: Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis (clinicaltrials.gov) - Jan 10, 2018
P=N/A, N=12, Terminated, Sponsor: Asan Medical Center
Active, not recruiting --> Terminated; Replaced by another protocol Trial primary completion date: Feb 2018 --> May 2016
- | Campath (alemtuzumab) / Sanofi, Atgam (equine anti-thymocyte globulin) / Pfizer
Trial completion, Enrollment change: Stem Cell Transplant for Immunologic or Histiocytic Disorders (clinicaltrials.gov) - Dec 28, 2017
P2, N=19, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Feb 2018 --> May 2016 Active, not recruiting --> Completed | N=30 --> 19
- etoposide IV / Generic mfg.
Enrollment change, Trial termination: Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis (clinicaltrials.gov) - May 24, 2016
P=N/A, N=12, Terminated, Sponsor: Asan Medical Center
Active, not recruiting --> Completed | N=30 --> 19 N=50 --> 12 | Recruiting --> Terminated; The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.
- | Biomarker, Trial completion, Trial primary completion date: Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma (clinicaltrials.gov) - May 19, 2016
P=N/A, N=50, Completed, Sponsor: Children's Oncology Group
N=50 --> 12 | Recruiting --> Terminated; The PI resigned the institute, and the rest investigators at the institute decided to terminate the study. Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- Trial completion: Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity (clinicaltrials.gov) - Jul 1, 2015
P=N/A, N=120, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed
- etoposide IV / Generic mfg.
Trial primary completion date: Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=50, Recruiting, Sponsor: Asan Medical Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Feb 2018
- Enrollment closed, Trial primary completion date: Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=120, Active, not recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
Trial primary completion date: Feb 2015 --> Feb 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2013 --> Mar 2014
- Enrollment change: T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders (clinicaltrials.gov) - Mar 26, 2014
P2/3, N=22, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2013 --> Mar 2014 N=40 --> 22
- | Enrollment closed: Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 (clinicaltrials.gov) - Nov 21, 2012
P3, N=300, Active, not recruiting, Sponsor: Karolinska University Hospital
N=40 --> 22 Recruiting --> Active, not recruiting
- Campath (alemtuzumab) / Sanofi, Atgam (equine anti-thymocyte globulin) / Pfizer
Enrollment closed: Stem Cell Transplant for Immunologic or Histiocytic Disorders (clinicaltrials.gov) - Oct 25, 2012
P2, N=30, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed: T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders (clinicaltrials.gov) - Sep 4, 2012
P2/3, N=22, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Biomarker, Enrollment closed: Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma (clinicaltrials.gov) - Dec 13, 2011
P=N/A, N=50, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting